Key result
SRT1720 treatment improved cardiac function and attenuated deleterious left ventricular remodeling in a mouse model of pressure overload.
Why the study?
Does pharmacological activation of SIRT1 with SRT1720 attenuate cardiac fibrosis and improve cardiac function in a rodent pressure overload model?
RCT
randomized
Does pharmacological activation of SIRT1 with SRT1720 attenuate cardiac fibrosis and improve cardiac function in a rodent pressure overload model?
Pharmacological activation of SIRT1 with SRT1720 attenuates cardiac fibrosis and improves cardiac function in a mouse model of pressure overload, suggesting a potential therapeutic strategy for heart failure.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for SIRT1 activation in HF; leaves open clinical translation from rodent pressure-overload models.
Bugyei‐Twum et al. (2018) conducted an RCT in Pressure overload / Heart failure. SRT1720 vs. Vehicle was evaluated on Cardiac function and left ventricular remodelling. SRT1720 treatment improved cardiac function and attenuated deleterious left ventricular remodeling in a mouse model of pressure overload.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: